Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27627034 | 0.87 | ALOX5 (0.64) | ALOX5L3MBTL1GAASMN1; SMN2LMNA | |
| SCHEMBL30513891 | 0.86 | ALOX5 (0.72) | ALOX5L3MBTL1GAASMN1; SMN2LMNA | |
| SCHEMBL10117829 | 0.85 | ALOX5 (0.71) | ALOX5L3MBTL1GAASMN1; SMN2LMNA | |
| SCHEMBL21055737 | 0.83 | ALOX5 (0.63) | ALOX5L3MBTL1GAASMN1; SMN2LMNA | |
| SCHEMBL13042440 | 0.83 | ALOX5 (0.68) | ALOX5GAASMN1; SMN2LMNACYP3A4 | |
| SCHEMBL11418048 | 0.82 | ALOX5 (0.73) | ALOX5L3MBTL1GAASMN1; SMN2LMNA | |
| SCHEMBL1531522 | 0.82 | ALOX5 (1.00) | ALOX5L3MBTL1GAASMN1; SMN2LMNA | |
| SCHEMBL19720259 | 0.82 | ALOX5 (0.62) | ALOX5L3MBTL1GAASMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL28067312 | 0.82 | ALOX5 (0.61) | ALOX5L3MBTL1GAASMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL8957363 | 0.81 | ALOX5 (0.96) | ALOX5L3MBTL1GAASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119095925-A | Two-component (2K) acrylic composition comprising biorenewable monomers | 汉高股份有限及两合公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-119095894-A | Two-component (2K) acrylic composition comprising thermoplastic polyurethane | 汉高股份有限及两合公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2023142013-A1 | TWO-PART POLYURETHANE- (METH) ACRYLIC HYBRID ADHESIVE COMPOSITION | HENKEL AG & CO. KGAA (DE) | 2023-08-03 | — | — | WO | disclosed |
| CN-116323723-A | Curing accelerators for anaerobically curable compositions | 汉高股份有限及两合公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-114667304-A | One-component (1K) anaerobically curable compositions | 汉高股份有限及两合公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-111417693-B | Curing accelerators for anaerobically curable compositions | 汉高知识产权控股有限责任公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-111417693-A | Curing accelerators for anaerobically curable compositions | 汉高知识产权控股有限责任公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-107148411-B | Phenylhydrazine/anhydride adducts and anaerobically curable compositions using phenylhydrazine/anhydride adducts | 汉高知识产权控股有限责任公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-106715559-B | Curing accelerators for anaerobic curable compositions | 汉高知识产权控股有限责任公司 | 2020-02-28 | — | — | CN | disclosed |
| EP-2285760-B1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2018-02-21 | — | — | EP | disclosed |
| WO-2009137448-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137448-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137444-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137444-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090277356-A1 | Cure Accelerators for Anaerobic Curable Compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090277356-A1 | Cure Accelerators for Anaerobic Curable Compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090277356-A1 | Cure Accelerators for Anaerobic Curable Compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2097382-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | Sanofi-Aventis (FR) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077507-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939181-A1 | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090277356-A1 | Cure Accelerators for Anaerobic Curable Compositions | ACLY, ACAD9, CCNY | ALOX5 903/4885L3MBTL1 3534/4885GAA 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.